Quality of life in patients with allergic asthma on treatment with omalizumab
| Autor: | Nadia Karina Aguilar-Hinojosa, Georgina Alejandra Sánchez-Tec |
|---|---|
| Jazyk: | English<br />Spanish; Castilian |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Revista Alergia México, Vol 65, Iss 4, Pp 349-356 (2018) |
| Druh dokumentu: | article |
| ISSN: | 0002-5151 2448-9190 |
| DOI: | 10.29262/ram.v65i4.382 |
| Popis: | Background: Omalizumab is a monoclonal antibody that controls severe allergic asthma symptoms and reduces exacerbations. Objective: To analyze quality of life and respiratory function improvement using the mini-AQLQ questionnaire and spirometry, with the use omalizumab as complementary therapy to a treatment with inhaled corticosteroids and long-acting beta 2 agonists. Methods: Of 30 patients with severe asthma (90 % of females, mean age, 49.1 years) the evolution of severe asthma diagnosis ranged from 1 to 24 years (average 8.3 years). All of them had at least one cutaneous or IgE-specific test that was positive to a usual aeroallergen, had total IgE determined and underwent spirometry. The mini-AQLQ questionnaire was applied and forced expiratory volume in 1 second (FEV1) was determined at baseline and at 52 weeks of omalizumab administration, the average dose of which was 550 mg, with biweekly or monthly administration. Results: There was statistically significant improvement (p = 0.013) in the mini-AQLQ after 52 weeks, with an overall score of 4.5, mainly in the emotional (p = 0.0073) and environmental dimensions (p = 0.00014). There were no significant changes in FEV1. Obesity was observed in 63 % of patients, and overweight in 26 %. Conclusions: Omalizumab improved patient quality of life, with no significant changes in FEV1, probably due to obesity. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|